NextCure, Inc. (NASDAQ:NXTC) Short Interest Down 32.1% in November

NextCure, Inc. (NASDAQ:NXTC) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 44,900 shares, a drop of 32.1% from the October 31st total of 66,100 shares. Based on an average trading volume of 43,000 shares, the short-interest ratio is currently 1.0 days. Approximately 0.2% of the company’s shares are short sold.

NextCure Price Performance

Shares of NXTC stock remained flat at $1.17 on Friday. The company had a trading volume of 12,594 shares, compared to its average volume of 65,145. The firm has a 50-day moving average of $1.34 and a 200 day moving average of $1.47. NextCure has a 52-week low of $1.03 and a 52-week high of $2.57. The firm has a market capitalization of $32.77 million, a price-to-earnings ratio of -0.56 and a beta of 0.80.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on shares of NextCure from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, November 11th.

Institutional Trading of NextCure

Several hedge funds have recently made changes to their positions in NXTC. Logos Global Management LP raised its stake in shares of NextCure by 29.9% in the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock valued at $3,975,000 after acquiring an additional 575,000 shares in the last quarter. Affinity Asset Advisors LLC raised its position in NextCure by 24.2% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after purchasing an additional 328,918 shares in the last quarter. Vanguard Group Inc. raised its position in NextCure by 9.3% in the 1st quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after purchasing an additional 83,700 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of NextCure by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock valued at $735,000 after buying an additional 61,744 shares during the period. Finally, Armistice Capital LLC acquired a new position in shares of NextCure during the second quarter worth about $57,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.